A Comparison of the Rates of Clock-Based Nocturnal Hypoglycemia and Hypoglycemia While Asleep Among People Living with Diabetes: Findings from the Hypo-METRICS Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Gilberte Martine-Edith
  • Patrick Divilly
  • Natalie Zaremba
  • Uffe Søholm
  • Melanie Broadley
  • Petra Martina Baumann
  • Zeinab Mahmoudi
  • Mikel Gomes
  • Namam Ali
  • Evertine J. Abbink
  • Bastiaan de Galan
  • Julie Brøsen
  • Rory J. McCrimmon
  • Eric Renard
  • Simon Heller
  • Mark Evans
  • Monika Cigler
  • Julia K. Mader
  • Jane Speight
  • Frans Pouwer
  • Stephanie A. Amiel
  • Pratik Choudhary
Introduction: Nocturnal hypoglycemia is generally calculated between 00:00 and 06:00. However, those hours may not accurately reflect sleeping patterns and it is unknown whether this leads to bias. We therefore compared hypoglycemia rates while asleep with those of clock-based nocturnal hypoglycemia in adults with type 1 diabetes (T1D) or insulin-treated type 2 diabetes (T2D).
Methods: Participants from the Hypo-METRICS study wore a blinded continuous glucose monitor and a Fitbit Charge 4 activity monitor for 10 weeks. They recorded details of episodes of hypoglycemia using a smartphone app. Sensor-detected hypoglycemia (SDH) and person-reported hypoglycemia (PRH) were categorized as nocturnal (00:00–06:00 h) versus diurnal and while asleep versus awake defined by Fitbit sleeping intervals. Paired-sample Wilcoxon tests were used to examine the differences in hypoglycemia rates.
Results: A total of 574 participants [47% T1D, 45% women, 89% white, median (interquartile range) age 56 (45–66) years, and hemoglobin A1c 7.3% (6.8–8.0)] were included. Median sleep duration was 6.1 h (5.2–6.8), bedtime and waking time ∼23:30 and 07:30, respectively. There were higher median weekly rates of SDH and PRH while asleep than clock-based nocturnal SDH and PRH among people with T1D, especially for SDH <70 mg/dL (1.7 vs. 1.4, P < 0.001). Higher weekly rates of SDH while asleep than nocturnal SDH were found among people with T2D, especially for SDH <70 mg/dL (0.8 vs. 0.7, P < 0.001).
Conclusion: Using 00:00 to 06:00 as a proxy for sleeping hours may underestimate hypoglycemia while asleep. Future hypoglycemia research should consider the use of sleep trackers to record sleep and reflect hypoglycemia while asleep more accurately.
OriginalsprogEngelsk
TidsskriftDiabetes Technology and Therapeutics
ISSN1520-9156
DOI
StatusAccepteret/In press - 2024

Bibliografisk note

Funding Information:
This study represents independent research supported by the National Institute for Health and Care Research (NIHR) King's Clinical Research Facility and the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. Hypo-RESOLVE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), and The Leona M. and Harry B. Helmsley Charitable Trust. The industry partners supporting the JU include Abbott Diabetes Care, Eli Lilly, Medtronic, Novo Nordisk, and Sanofi-Aventis.

Funding Information:
G.M.E.'s position at King's College London is funded by a research grant from Novo Nordisk as part of their contribution to the Hypo-RESOLVE consortium. S.A.A. has served on advisory boards for Novo Nordisk and Medtronic and has spoken at an educational symposium sponsored by Sanofi. M.L.E. has served on advisory boards and/or received lecture fees and/or research support from Novo Nordisk, Eli Lilly, AstraZeneca, Medtronic, Dexcom, Ypsomed, Abbott Diabetes Care, Roche, NGM Pharma, Zucara, and Pila Pharma. U.P.B. has served on advisory boards and has received lecture fees from Sanofi and Novo Nordisk.

Publisher Copyright:
Copyright 2024, Mary Ann Liebert, Inc., publishers.

ID: 393138683